Headline News

 

Nirsevimab in Phase IIb Trial Reduced Respiratory Syncytial Virus Infections and Hospitalisations in Preterm Infants

Posted on August 03, 2020

FDA Authorizes First Tests that Estimate a Patient’s Antibodies from Past SARS-CoV-2 Infection

Posted on August 03, 2020

Pfizer and BioNTech Supply Japan with 120 Million Doses of  BNT162 mRNA-based Vaccine Candidate

Posted on July 31, 2020

Bristol Myers Squibb and Bluebird Bio Announce Submission of Biologics License Application to FDA for Idecabtagene Vicleucel for Adults with Relapsed and Refractory Multiple Myeloma

Posted on July 31, 2020

Novartis Receives Piqray® Approval in Europe – the First Targeted Medicine for HR+/HER2- Advanced Breast Cancer With a PIK3CA Mutation

Posted on July 31, 2020

Merck’s Novel HIF-2α Inhibitor MK-6482 Granted Breakthrough Therapy Designation by FDA for Treatment of Certain Patients With Von Hippel-Lindau Disease- Associated Renal Cell Carcinoma

Posted on July 30, 2020

Johnson & Johnson COVID-19 Vaccine Candidate Demonstrates Robust Protection in Pre-clinical Studies

Posted on July 30, 2020

Calquence Recommended for EU Approval by CHMP for Chronic Lymphocytic Leukaemia

Posted on July 29, 2020

New Collaboration with AstraZeneca and Daiichi Sankyo to Develop and Commercialise New Antibody Drug Conjugate

Posted on July 29, 2020

Sandoz Announce Plans for Joint Investment to Help Strengthen Future of Antibiotics Manufacturing in Europe

Posted on July 28, 2020

Novartis Analysis Shows Wet AMD Patients Achieved Sustained Fluid Control Faster With Beovu® Versus Aflibercept

Posted on July 28, 2020

GSK Receives Positive Approval of Belantamab Mafodotin for the Treatment of Relapsed and Refractory Multiple Myeloma After CHMP Opinion Recommendation

Posted on July 27, 2020

FDA Approved First Cell-Based Gene Therapy For Adult Patients with Relapsed or Refractory MCL

Posted on July 27, 2020

Novavax and FUJIFILM Diosynth Biotechnologies Initiate Manufacturing of COVID-19 Vaccine Candidate

Posted on July 24, 2020

Novartis announces Phase III study of Jakavi®

Posted on July 24, 2020